Search
for
Sort by
Research 181–210 of 1000+
- Amphiregulin in Fibrotic Diseases and Cancer
- USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
- Integrative Analysis of the Metabolome and Transcriptome Reveals the Mechanism Underlying Differences in Skin Development Between the New Zealand Rabbit and the Rex Rabbit
- Unravelling the molecular basis for symbiotic signal transduction in legumes
- Identification of key genes and signaling pathways related to Hetian sheep wool density by RNA-seq technology
- Heat-killed Lacticaseibacillus paracasei GMNL-653 ameliorates human scalp health by regulating scalp microbiome
- Genomic prediction and genome-wide association studies of morphological traits and distraction index in Korean Sapsaree dogs
- Bee Venom Stimulates Growth Factor Release from Adipose-Derived Stem Cells to Promote Hair Growth
- Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System
- The Roles of Exosomes in Regulating Hair Follicle Growth
- Editor's evaluation: Crosstalk with keratinocytes causes GNAQ oncogene specificity in melanoma
- Protein profiling of forehead epidermal corneocytes distinguishes frontal fibrosing from androgenetic alopecia
- The JAK/STAT signaling pathway: from bench to clinic
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- An Overview of the Health Benefits, Extraction Methods and Improving the Properties of Pomegranate
- Opposing impacts on healthspan and longevity by limiting dietary selenium in telomere dysfunctional mice
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Under Development JAK Inhibitors for Dermatologic Diseases
- The significance of the apelinergic system in doxorubicin-induced cardiotoxicity
- Renal tubular dysfunction presenting as recurrent hypokalemic periodic quadriparesis in systemic lupus erythematosus
- Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
- Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Combination Therapy for Extensive Tumoral Calcinosis in Juvenile Dermatomyositis
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study